G12C mutation
![Krazati, Miratiās Lead KRAS Drug, Faces Rejection in Europe](https://pharmtales.com/wp-content/uploads/2023/07/Miratis-KRAS-Inhibitor-Krazati-Faces-Rejection-in-Europe.jpg)
Mirati’s KRAS Inhibitor Krazati Faces Rejection in Europe
SG Tylor
Source – Mirati Therapeutics Mirati Therapeutics has faced a setback in its quest to market its lead KRAS inhibitor Krazati, ...
Source – Mirati Therapeutics Mirati Therapeutics has faced a setback in its quest to market its lead KRAS inhibitor Krazati, ...